Positive outcomes in court for Boston with Guidant settlement and Johnson & Johnson dispute
This article was originally published in Clinica
Executive Summary
Chipping away at the substantial litigation it had inherited from Guidant, Boston Scientific has reached an agreement with the Attorneys General of 35 US states and the District of Columbia to settle investigations related to the recall of potentially faulty defibrillators manufactured by the acquired company.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.